Business
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)
Expect to enroll approximately 160 subjects and study 3 doses of Haduvio against placebo Primary efficacy endpoint is the relative change in 24-hour cough
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Expect to enroll approximately 160 subjects and study 3 doses of Haduvio against placebo\nPrimary efficacy endpoint is the relative change in 24-hour cough frequency of Haduvio versus placebo\nNEW HAVEN, Conn., Dec. 5, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis, today announced the initiation of its Phase 2b CORAL clinical trial evaluating three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough. This Phase 2b trial builds on the positive results from the Phase 2a CANAL trial, which demonstrated a statistically significant reduction in daytime cough frequency by 75.1%, a 52.5% difference from placebo (p","length":2011,"tagName":"div"}]